Login to Your Account

Clinic Roundup

Monday, February 11, 2013
• RNL BIO Co. Ltd., of Seoul, South Korea, said it filed an investigational new drug application with Korean regulators to start Phase II and Phase III studies testing its RNL-Astrostem stem cell drug in patients with cerebral palsy.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription